(Date:5/15/2008)... a more convenient regimen than current therapies ... The drug ustekinumab has been shown to be a very ...rate-to-severe psoriasis in two studies published ...umab works by binding to two interleukins, protein...mmatory reactions in diseases like psoriasis. The ...
(Date:5/15/2008)...leadership in proposing prescription,drug marketin...PRNewswire-USNewswire/ -- AARP strongly believes,N...vernor,s prescription,marketing reform proposals w...al companies have over prescribing decisions that ...eatment they receive., The reforms include bannin...
(Date:5/15/2008)...ide cancer incidence, researchers at the Moores Ca... (UCSD) and the Department of Family and Preventiv...deficiency in exposure to sunlight, specifically u...posure triggers photosynthesis of vitamin D3 in th...hrough diet and supplements. , Approximately 1,...
(Date:5/15/2008)...e-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: VRUS ),... to,discovering, developing and commercializing no...dited financial results for the second fiscal,quar...t loss attributable,to common stockholders of $12....ded March 31, 2008, as compared to a net loss attr...
Breaking Medicine News(10 mins):Health News:Drug Works Well for Moderate-to-Severe Psoriasis 2Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2Health News:UCSD researchers show link between vitamin D status, breast cancer 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8(Date:5/15/2008)...A Trial data reports in third quarter ...RNewswire-FirstCall/ -- VIA Pharmaceuticals,Inc. ...on the development of,compounds for the treatment ... has completed patient enrollment in its acute cor...f three Phase 2 trials investigating VIA-2291,the...
(Date:5/15/2008)... Meeting of The American Society of Ped...INE, Calif., May 15 /- IDM ...announced the presentation of updated data,from a ...e (L-MTP-PE) in,patients with lung metastases as a... and often fatal bone tumor that typically affects...
(Date:5/14/2008)...swire-FirstCall/ -- Progen,Pharmaceuticals Limited...Company has resumed patient enrolment in the phase...polyamine analogue, PG-11047 (formerly CGC-11047),...mmenced development of PG-11047 - the lead clinica...llowing its acquisition of,Cellgate, Inc earlier t...
(Date:5/14/2008)...PacificGMP, the leader in utilizing,single-use bio...ts client,partners, announced today that it has co...ng practices) standards for a Trius Therapeutics P...orked closely with Trius on this GMP fill,project,...nd complete,within a narrow deadline," said Leigh ...
Breaking Medicine Technology:VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2PacificGMP Completes GMP Product Fill for Trius Therapeutics 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 1094 1VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 1094 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 1094 3Grid computing offers new hope in race against bird flu 3001 1Grid computing offers new hope in race against bird flu 3001 2Fungus genome yielding answers to protect grains people and animals 699 1Fungus genome yielding answers to protect grains people and animals 699 2Fungus genome yielding answers to protect grains people and animals 699 3The reservoir of Marburg virus identified in a species of fruit bat 697 1The reservoir of Marburg virus identified in a species of fruit bat 697 2The reservoir of Marburg virus identified in a species of fruit bat 697 3...ed on Glucose Homeostasis Effects in,Normal and Di...-FirstCall/ -- In a 14-day,Phase IIa study of the...tional compound dapagliflozin, a selective inhibit...inistered alone or,concomitantly with metformin in...s due to adverse events and no serious adverse,eve...
.../PRNewswire/ -- Novagali Pharma, an,emerging pharm...sents positive results of its pivotal phase III cl...linical study of Vekacia(R) in,children suffering ...Afro-Asian Congress of ophthalmology (AACO) held f...KC is a severe form of chronic allergic conjunctiv...
Other Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4Transfuse-ID, a bedside Transfusion Verification System, is used by hospitals to ensure that a patient receives the specific unit(s) of blood that was typed and crossmatched for them. It has th
...stem helps ensure a safe care environment by autom...he unit dose level. The automated process and reli...ion and handling of all items, including vials, am...reparations and more. This saves valuable time for...
...nsfusion Safety Management system ensures your pat...care. , BloodTrack SafeTx uses the AutoPPI b...nt from sample collection to transfusion. SafeTx c...uces the need for bedside paperwork and associated...
wBloodCare provides functionality at the bedside to ensure that the correct patient receives the correct blood product.
Medicine Products: